LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article ; Online: Bis{[amino-(iminium-yl)meth-yl]urea} tetra-kis-{2-[(di-methyl-amino)(iminium-yl)meth-yl]guanidine} di-μ

Pérez-Benítez, Aarón / Ariza-Ramírez, Jorge Luis / Fortis-Valera, Monserrat / Arroyo-Carmona, Rosa Elena / Martínez de la Luz, María Isabel / Ramírez-Contreras, Diego / Bernès, Sylvain

IUCrData

2022 Volume 7, Issue Pt 6, Page(s) x220627

Abstract: The title compound, ( ... ...

Abstract	The title compound, (C
Language	English
Publishing date	2022-06-24
Publishing country	England
Document type	Journal Article
ISSN	2414-3146
ISSN (online)	2414-3146
DOI	10.1107/S2414314622006277
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.

Qiu, Ji / Engelbrektson, Anna / Song, Lusheng / Park, Jin / Murugan, Vel / Williams, Stacy / Chung, Yunro / Pompa-Mera, Ericka Nelly / Sandoval-Ramirez, Jorge Luis / Mata-Marin, Jose Antonio / Gaytan-Martinez, Jesus / Troiani, Eliana / Sanguinetti, Maurizio / Roncada, Paola / Urbani, Andrea / Moretti, Giacomo / Torres, Javier / LaBaer, Joshua

Microbiology spectrum

2023 Volume 11, Issue 4, Page(s) e0469022

Abstract: Patients with 2019 coronavirus disease (COVID-19) exhibit a broad spectrum of clinical presentations. A person's antimicrobial antibody profile, as partially shaped by past infection or vaccination, can reflect the immune system health that is critical ... ...

Abstract	Patients with 2019 coronavirus disease (COVID-19) exhibit a broad spectrum of clinical presentations. A person's antimicrobial antibody profile, as partially shaped by past infection or vaccination, can reflect the immune system health that is critical to control and resolve the infection. We performed an explorative immunoproteomics study using microbial protein arrays displaying 318 full-length antigens from 77 viruses and 3 bacteria. We compared antimicrobial antibody profiles between 135 patients with mild COVID-19 disease and 215 patients with severe disease in 3 independent cohorts from Mexico and Italy. Severe disease patients were older with higher prevalence of comorbidities. We confirmed that severe disease patients elicited a stronger anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) response. We showed that antibodies against HCoV-229E and HcoV-NL63 but not against HcoV-HKU1 and HcoV-OC43 were also higher in those who had severe disease. We revealed that for a set of IgG and IgA antibodies targeting coronaviruses, herpesviruses, and other respiratory viruses, a subgroup of patients with the highest reactivity levels had a greater incidence of severe disease compared to those with mild disease across all three cohorts. On the contrary, fewer antibodies showed consistent greater prevalence in mild disease in all 3 cohorts.
MeSH term(s)	Humans ; COVID-19/epidemiology ; SARS-CoV-2 ; Coronavirus 229E, Human ; Coronavirus OC43, Human ; Antibodies, Viral
Chemical Substances	Antibodies, Viral
Language	English
Publishing date	2023-06-06
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.04690-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.

Blanco Vela, Claudia Isabel / Poo Ramírez, Jorge Luis

Annals of hepatology

2012 Volume 10 Suppl 2, Page(s) S55–9

Abstract: Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (HE) have focused on reducing ... ...

Abstract	Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (HE) have focused on reducing ammonia generation from the bowel rather than on manipulating systemic mechanisms involved in ammonia metabolism. Administration of L-ornithine L-aspartate (LOLA) improves mental status and decreases serum and spinal fluid ammonia levels by stimulating both the urea cycle and glutamine (Gln) synthesis, which are key metabolic pathways in ammonia detoxification. LOLA was shown to be superior to a placebo for management of HE, and the results of several clinical trials suggest that its effectiveness could be higher with the more severe grades of this syndrome. Compared with the standard treatment, LOLA is effective not only in reducing hyperammonemia and the severity of this disease, but also in improving the patient's perceived quality of life. Therefore, LOLA is a promising alternative for the management of HE.
MeSH term(s)	Administration, Oral ; Ammonia/metabolism ; Dipeptides/administration & dosage ; Dipeptides/therapeutic use ; Glutamine/metabolism ; Hepatic Encephalopathy/drug therapy ; Hepatic Encephalopathy/etiology ; Hepatic Encephalopathy/metabolism ; Humans ; Hyperammonemia/drug therapy ; Hyperammonemia/etiology ; Hyperammonemia/metabolism ; Liver Cirrhosis/complications ; Quality of Life ; Severity of Illness Index ; Treatment Outcome ; Urea/metabolism
Chemical Substances	Dipeptides ; Glutamine (0RH81L854J) ; Ammonia (7664-41-7) ; Urea (8W8T17847W) ; ornithylaspartate (JA08T3B97O)
Language	English
Publishing date	2012-01-05
Publishing country	Mexico
Document type	Journal Article
ZDB-ID	2188733-0
ISSN	1665-2681
ISSN	1665-2681
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.

Sandoval-Ramirez, Jorge Luis / Mata-Marín, José Antonio / Huerta García, Gloria / Gaytán-Martínez, Jesús Enrique

Journal of infection in developing countries

2015 Volume 9, Issue 3, Page(s) 267–273

Abstract: Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted ... ...

Abstract	Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective. Methodology: This was a retrospective cohort study at a infectious disease center in Mexico City. Patients were included if they had received peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. Age, sex, body mass index, AST platelet ratio index, HCV RNA viral load, levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts of the subjects were assessed before treatment and at weeks 4, 12, 24, 48, and 6 months post treatment. Results: Eighty-seven patients met the inclusion criteria. A sustained virological response (SVR) occurred in 33 (38%) of them, 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). Seventeen patients (20%) relapsed, 7 (41%) of those given peginterferon alfa-2a and 10 (59%) of those given peginterferon alfa-2b (p = 0.76); 27 (31%) patients were non-responders (p = 0.09). The rates of anemia, thrombocytopenia, and leukopenia were similar in both groups. Conclusions: Similar SVR rates and frequencies of adverse events were observed. Either type of interferon can be used to treat HCV infection in the Mexican population.
MeSH term(s)	Adult ; Antiviral Agents/therapeutic use ; Blood Chemical Analysis ; Cohort Studies ; Female ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/drug therapy ; Humans ; Interferon-alpha/therapeutic use ; Male ; Mexico ; Middle Aged ; Polyethylene Glycols/therapeutic use ; RNA, Viral/blood ; Recombinant Proteins/therapeutic use ; Recurrence ; Retrospective Studies ; Ribavirin/therapeutic use ; Treatment Outcome ; Viral Load
Chemical Substances	Antiviral Agents ; Interferon-alpha ; RNA, Viral ; Recombinant Proteins ; Polyethylene Glycols (30IQX730WE) ; Ribavirin (49717AWG6K) ; peginterferon alfa-2b (G8RGG88B68) ; peginterferon alfa-2a (Q46947FE7K)
Language	English
Publishing date	2015-03-15
Publishing country	Italy
Document type	Clinical Study ; Comparative Study ; Journal Article
ZDB-ID	2394024-4
ISSN	1972-2680 ; 2036-6590
ISSN (online)	1972-2680
ISSN	2036-6590
DOI	10.3855/jidc.5284
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Psychometry and Cut-off Points of the Jefferson Scale of Empathy in Medical Students in Central America and the Caribbean.

Díaz-Narváez, Víctor P / Calzadilla-Núñez, Aracelis / Reyes-Reyes, Alejandro / Silva-Vetri, María G / Torres-Martínez, Pilar / González-Díaz, Eugenia S / Alonso-Palacio, Luz M / Bilbao-Ramírez, Jorge Luis / Estrada-Méndez, Nuvia / Aparicio, Dilia Esther / Fajardo-Ramos, Elizabeth / Ferrero-Otero, Juan Carlos / Barrera-Gil, Douglas / Ríos-García, Ana Liliana

Puerto Rico health sciences journal

2022 Volume 41, Issue 1, Page(s) 22–28

Abstract: Objective: The objective of this study was to determine cut-off points that can be used to differentiate measures of empathy, which would then be classified as high, medium, or low. To do so, we used data from students from 7 medical schools in Colombia, ...

Abstract	Objective: The objective of this study was to determine cut-off points that can be used to differentiate measures of empathy, which would then be classified as high, medium, or low. To do so, we used data from students from 7 medical schools in Colombia, El Salvador, and the Dominican Republic, after determining the psychometric properties of the 3-dimensional model of empathy in the Jefferson Scale of Empathy, S-version (for medical students). Materials and methods: This non-experimental descriptive study had a sample that consisted of 6291 students. The structure and factor invariance were analyzed by country and sex. A hierarchical cluster analysis and a bifactorial analysis of variance were applied. Results: The measure of empathy was reliable on the global scale (α = .82; ω = .88). A confirmatory factor analysis showed that the original model was replicable and adjusted to the data (comparative fit index [CFI] = .90; goodness of fit index = .94), while the multigroup analysis allowed to assume an invariant factor structure by country and gender (ΔCFI < .01). Tables were constructed with cut off points for empathy and its dimensions. Discussion and conclusion: Our study solves the problem of comparing the scores and the levels of empathy observed in the medical students at different schools of medicine, making said comparisons within and between countries and between genders. The instrument used has adequate psychometric properties and the cut-off values obtained allow the classifying of people with lower or higher levels of empathy.
MeSH term(s)	Dominican Republic ; Empathy ; Female ; Humans ; Male ; Psychometrics ; Reproducibility of Results ; Students, Medical ; Surveys and Questionnaires
Language	English
Publishing date	2022-04-29
Publishing country	Puerto Rico
Document type	Journal Article
ZDB-ID	639137-0
ISSN	2373-6011 ; 0738-0658
ISSN (online)	2373-6011
ISSN	0738-0658
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 3093: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy.

Bautista-Martínez, Jonathan Saúl / Mata-Marín, José Antonio / Sandoval-Ramírez, Jorge Luis / Chaparro-Sánchez, Alberto / Manjarrez-Téllez, Bulmaro / Uribe-Noguez, Luis Antonio / Gaytán-Martínez, Jesús / Núñez-Armendáriz, Mireya / Cruz-Sánchez, Arcenio / Núñez-Rodríguez, Nohemí / Iván, Martínez-Abarca / Morales-González, Georgina Selene / Álvarez-Mendoza, Juan Pablo / Pérez-Barragán, Edgar / Ríos-De Los Ríos, Jussara / Contreras-Chávez, Gerson Gabriel / Tapia-Magallanes, Denisse Marielle / Ribas-Aparicio, Rosa Maria / Díaz-López, Mónica /

Olivares-Labastida, Azucena / Gómez-Delgado, Alejandro / Torres, Javier / Miranda-Duarte, Antonio / Zenteno, Juan C / Pompa-Mera, Ericka Nelly

Pharmacogenetics and genomics

2022 Volume 32, Issue 3, Page(s) 101–110

Abstract: Objective: To investigate the impact of single nucleotide polymorphisms (SNPs) from APOA5, APOC3, CETP, ATP binding cassette transporter A1 and SIK3 genes in the development of hypertriglyceridemia in HIV patients under antiretroviral therapy.: ... ...

Abstract	Objective: To investigate the impact of single nucleotide polymorphisms (SNPs) from APOA5, APOC3, CETP, ATP binding cassette transporter A1 and SIK3 genes in the development of hypertriglyceridemia in HIV patients under antiretroviral therapy. Material and methods: A case-control study was developed. Leukocytic genomic DNA was extracted and genotyping for SNPs rs662799, rs964184, rs5128, rs2854116, rs2854117, rs3764261, rs4149310, rs4149267 and rs139961185 was performed by real time-PCR using TaqMan allelic discrimination assays, in Mexican mestizo patients with HIV infection, with hypertriglyceridemia (>1.7 mmol/L) under antiretroviral therapy. Genetic variants were also investigated in a control group of normolipidemic HIV patients (≤ 1.7 mmol/L). Haplotypes and gene interactions were analyzed. Results: A total of 602 HIV patients were genotyped (316 cases and 286 controls). Age and antiretroviral regimen based on protease inhibitors were associated with hypertriglyceridemia (P = 0.0001 and P = 0.0002. respectively). SNP rs964184 GG genotype in APOA5 gene exhibited the highest association with hypertriglyceridemia risk (OR, 3.2, 95% CI, 1.7-5.8, P = 0.0001); followed by SNP rs139961185 in SIK3 gene (OR = 2.3; (95% CI, 1.1-4.8; P = 0.03 for AA vs. AG genotype; and APOC3 rs5128 GG genotype, (OR, 2.2; 95% CI, 1.1-4.9; P = 0.04) under codominant models. These associations were maintained in the adjusted analysis by age and protease inhibitors based antiretroviral regimens. Conclusions: This study reveals an association between rs964184 in APOA5; rs5128 in APOC3 and rs139961185 in SIK3 and high triglyceride concentrations in Mexican HIV-patients receiving protease inhibitors. These genetic factors may influence the adverse effects related to antiretroviral therapy.
MeSH term(s)	ATP Binding Cassette Transporter 1/genetics ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; Apolipoprotein A-V/genetics ; Apolipoprotein C-III/genetics ; Case-Control Studies ; Cholesterol Ester Transfer Proteins/genetics ; Genotype ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Infections/genetics ; Humans ; Hypertriglyceridemia/chemically induced ; Hypertriglyceridemia/genetics ; Mexico ; Polymorphism, Single Nucleotide ; Protein Kinases ; Triglycerides
Chemical Substances	ABCA1 protein, human ; APOA5 protein, human ; ATP Binding Cassette Transporter 1 ; Anti-HIV Agents ; Apolipoprotein A-V ; Apolipoprotein C-III ; CETP protein, human ; Cholesterol Ester Transfer Proteins ; Triglycerides ; Protein Kinases (EC 2.7.-) ; SIK3 protein, human (EC 2.7.11.1)
Language	English
Publishing date	2022-01-05
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2175826-8
ISSN	1744-6880 ; 0960-314X ; 1744-6872
ISSN (online)	1744-6880
ISSN	0960-314X ; 1744-6872
DOI	10.1097/FPC.0000000000000458
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3660: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

Mata-Marín, José Antonio / Smeke, Ariane Estrella Weiser / Rodriguez, Mariana Rotzinger / Chávez-García, Marcelino / Banda-Lara, Marco Isaac / Rios, Alma Minerva Pérez / Nuñez-Rodríguez, Nohemí / Domínguez-Hermosillo, Juan Carlos / Sánchez, Alberto Chaparro / Juarez-Kasusky, Irene / Herrera, Javier Enrique Cruz / Ramírez, Jorge Luis Sandoval / Gaytán-Martínez, Jesús

Drugs in R&D

2017 Volume 17, Issue 1, Page(s) 225–231

Abstract: Objective: We evaluated the effectiveness of a raltegravir (RAL)-containing regimen plus an optimized background regimen in HIV-1 highly treatment-experienced patients.: Design: A retrospective cohort, multicentre study was conducted.: Methods: ... ...

Abstract	Objective: We evaluated the effectiveness of a raltegravir (RAL)-containing regimen plus an optimized background regimen in HIV-1 highly treatment-experienced patients. Design: A retrospective cohort, multicentre study was conducted. Methods: Adult (>16 years old) HIV treatment-experience patients starting therapy with a RAL-containing regimen were included. Effectiveness was evaluated as the percentage of patients with an undetectable HIV-1 RNA viral load (<50 and <200 copies/mL) after 48 weeks, and changes in CD4+ cell counts. We evaluated the risk factors associated with treatment failure. Results: Of the 107 patients in the cohort, 86% were men, the median age was 45 years [interquartile range (IQR) 40-52] and the median number of previous regimens was six (IQR 4-7). After 48 weeks of treatment, 73% (IQR 63-80%) of patients (n = 78) had a viral load of <50 copies/mL and 85% (IQR 77-90%) (n = 91) had <200 copies/mL. In a logistic regression model, risk factors associated with a virological outcome of HIV-1 RNA of <200 copies/mL were age >40 years [odds ratio (OR) 5.61; 95% confidence interval (CI) 1.61-18.84; P = 0.006] and use of tenofovir in the regimen (OR 0.16; 95% CI 0.03-0.80; P = 0.026). Conclusions: In this Mexican cohort, RAL achieved high rates of virological suppression and an increase in CD4+ cell count in highly treatment-experienced patients infected with HIV-1. Age >40 years was associated with a good virological outcome, contrary to tenofovir use, which was associated with a poor virological outcome.
MeSH term(s)	Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/therapeutic use ; Cohort Studies ; Female ; HIV Infections/drug therapy ; HIV-1/drug effects ; Humans ; Male ; Middle Aged ; Raltegravir Potassium/administration & dosage ; Raltegravir Potassium/therapeutic use ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Chemical Substances	Anti-HIV Agents ; Raltegravir Potassium (43Y000U234)
Language	English
Publishing date	2017-03
Publishing country	New Zealand
Document type	Journal Article ; Multicenter Study
ZDB-ID	2020476-0
ISSN	1179-6901 ; 1174-5886
ISSN (online)	1179-6901
ISSN	1174-5886
DOI	10.1007/s40268-017-0174-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5262: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Risk factors associated with mortality in patients infected with influenza A/H1N1 in Mexico.

Mata-Marín, Luis Alberto / Mata-Marín, José Antonio / Vásquez-Mota, Velasco Claudia / Arroyo-Anduiza, Carla Ileana / Gaytán-Martínez, Jesús Enrique / Manjarrez-Téllez, Bulmaro / Ochoa-Carrera, Luis Alberto / Sandoval-Ramírez, Jorge Luis

BMC research notes

2015 Volume 8, Page(s) 432

Abstract: Background: Influenza virus pandemics vary dramatically in their severity and mortality. Thus, it is very important to identify populations with high risks of developing severe illness to reduce mortality in future pandemics. The purpose was to ... ...

Abstract	Background: Influenza virus pandemics vary dramatically in their severity and mortality. Thus, it is very important to identify populations with high risks of developing severe illness to reduce mortality in future pandemics. The purpose was to determine the mortality-associated risk factors in hospitalized Mexican patients infected with influenza A/H1N1. Results: The risk factors associated with mortality were: male sex [odds ratio (OR) = 5.25, confidence interval (CI) = 1.22-28.95], medical attention delayed >3 days (OR = 9.9, CI = 1.51-64.52), anti-flu therapy delayed >3 days (OR = 10.0, CI = 1.07-93.43), admission to intensive care unit (ICU) (OR = 9.9, CI = 1.51-64.52) and creatinine levels >1.0 mg/dL when admitted to hospital (OR = 11.2, CI = 1.05-120.32). After adjusting for the effects of potentially confounding variables in a logistic regression model, delayed medical attention (OR = 13.91, CI = 1.09-41.42, p = 0.044) and ICU hospitalization (OR = 11.02, CI = 1.59-76.25, p = 0.015) were the only predictors of mortality. Conclusion: Early medical attention is essential for reducing the mortality risk in patients with influenza A/H1N1, while a requirement for ICU management increases the risk.
MeSH term(s)	Adult ; Female ; Humans ; Influenza A Virus, H1N1 Subtype/physiology ; Influenza, Human/mortality ; Influenza, Human/virology ; Male ; Mexico/epidemiology ; Middle Aged ; Multivariate Analysis ; Risk Factors ; Young Adult
Language	English
Publishing date	2015-09-11
Publishing country	England
Document type	Journal Article
ZDB-ID	2413336-X
ISSN	1756-0500 ; 1756-0500
ISSN (online)	1756-0500
ISSN	1756-0500
DOI	10.1186/s13104-015-1349-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Prevalence of antibodies against Treponema pallidum among HIV-positive patients in a tertiary care hospital in Mexico.

Mata-Marín, José Antonio / Sandoval-Sánchez, Juan Joel / Huerta-García, Gloria / Arroyo-Anduiza, Carla Ileana / Alcalá-Martínez, Enrique / Mata-Marín, Luis Alberto / Sandoval-Ramirez, Jorge Luis / Gaytán-Martínez, Jesús

International journal of STD & AIDS

2015 Volume 26, Issue 2, Page(s) 81–85

Abstract: Our objective was to determine the seroprevalence of syphilis among HIV-infected patients in a tertiary care hospital in Mexico City. A cross-sectional study was developed, and 318 HIV-positive patients were evaluated from January to February 2013 at ... ...

Abstract	Our objective was to determine the seroprevalence of syphilis among HIV-infected patients in a tertiary care hospital in Mexico City. A cross-sectional study was developed, and 318 HIV-positive patients were evaluated from January to February 2013 at Hospital de Infectología, National Medical Center 'La Raza' (a tertiary care hospital specialising in infectious diseases in Mexico City). Laboratory data were screened for the detection of antibodies against Treponema pallidum. Patients completed a questionnaire relating to socio-demographic data and factors associated with syphilis. Of the 318 patients, 83% were men. The mean age ± SD was 36 ± 11 years; 52% were men who have sex with men and 47% had undertaken higher education. The overall seroprevalence of syphilis among these patients was 25% (95% confidence interval 21%, 30%). Men who have sex with men had a significantly higher seroprevalence (30% vs. 15%, p = 0.009). We conclude that, in Mexico, there is a high seroprevalence of syphilis antibodies in HIV-infected patients and that men who have sex with men are the group most affected.
MeSH term(s)	Adult ; Antibodies, Bacterial/blood ; Antibodies, Bacterial/immunology ; Cross-Sectional Studies ; Female ; HIV Infections/complications ; HIV Infections/epidemiology ; Homosexuality, Male/statistics & numerical data ; Humans ; Male ; Mexico/epidemiology ; Middle Aged ; Prevalence ; Seroepidemiologic Studies ; Sex Distribution ; Sexual Behavior ; Socioeconomic Factors ; Surveys and Questionnaires ; Syphilis/complications ; Syphilis/diagnosis ; Syphilis/epidemiology ; Syphilis/immunology ; Tertiary Healthcare ; Treponema pallidum/immunology
Chemical Substances	Antibodies, Bacterial
Language	English
Publishing date	2015-02
Publishing country	England
Document type	Journal Article
ZDB-ID	1018089-8
ISSN	1758-1052 ; 0956-4624
ISSN (online)	1758-1052
ISSN	0956-4624
DOI	10.1177/0956462414530888
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2829: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.

Huerta García, Gloria / Mata-Marín, José Antonio / Domínguez-Hermosillo, Juan Carlos / Chavez-García, Marcelino / Banda-Lara, Marco Issac / Nuñez-Rodríguez, Nohemi / Cruz-Herrera, Javier Enrique / Sandoval-Ramírez, Jorge Luis / Villagómez-Ruiz, Alfredo / Manjarrez-Tellez, Bulmaro / Gaytan-Martínez, Jesús Enrique

Journal of infection in developing countries

2016 Volume 10, Issue 6, Page(s) 605–611

Abstract: Introduction: Treatment options are limited for HIV-1-infected individuals who have received extensive previous antiretroviral therapy. ETV has shown significant clinical benefits in treatment-experienced HIV-1+ patients with antiretroviral resistance. ... ...

Abstract	Introduction: Treatment options are limited for HIV-1-infected individuals who have received extensive previous antiretroviral therapy. ETV has shown significant clinical benefits in treatment-experienced HIV-1+ patients with antiretroviral resistance. The aim of this study was to evaluate the effectiveness of ETV plus optimized background regimen in real-life conditions in a cohort of highly HIV-1 antiretroviral-experienced patients. Methodology: Retrospective cohort of treatment-experienced HIV-1-infected adults with virological failure who started therapy with an ETV-containing regimen. The effectiveness was evaluated using HIV-1 RNA viral load and changes in CD4+ cell count after 48 weeks of treatment. Results: Forty-two patients ≥ 16 years of age were included; 74% were men, and the median age was 45 years (IQR 41-53). All participants had prior non-nucleoside reverse transcriptase inhibitor use (55% nevirapine, 83%, efavirenz, and 28% both). Baseline median HIV-1 RNA viral load was 15,598 copies/mL (IQR 2651-84,175) and CD4+ cell count was 276 cells/mL (IQR 155-436). After 48 weeks of treatment, 90.5% (95% CI 78-96) of patients had HIV-1 RNA viral load < 200 copies/mL and 76% (95% CI 61-86) had < 50 copies/mL. CD4+ cell counts increased from baseline to 48 weeks of treatment to a median of 407 cells/mL (IQR 242-579); p < 0.001. Virological outcome was associated with virological failure at baseline HIV-1 RNA viral load ≥ 100,000 copies/mL (OR 7.6; 95% CI 1.2-44.80; p = 0.025). Conclusions: Our study provides clinically important evidence of the effectiveness and safety of ETV in highly antiretroviral-experienced HIV-1-infected patients.
MeSH term(s)	Adolescent ; Adult ; Aged ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/methods ; CD4 Lymphocyte Count ; Drug-Related Side Effects and Adverse Reactions ; Female ; HIV Infections/drug therapy ; Humans ; Male ; Middle Aged ; Pyridazines/adverse effects ; Pyridazines/therapeutic use ; RNA, Viral/blood ; Retrospective Studies ; Salvage Therapy/adverse effects ; Salvage Therapy/methods ; Treatment Outcome ; Viral Load ; Young Adult
Chemical Substances	Anti-HIV Agents ; Pyridazines ; RNA, Viral ; etravirine (0C50HW4FO1)
Language	English
Publishing date	2016-06-30
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2394024-4
ISSN	1972-2680 ; 2036-6590
ISSN (online)	1972-2680
ISSN	2036-6590
DOI	10.3855/jidc.7512
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito